Q
QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

30,459 signal articles · 150 in last 24h · 154,156 total before filter · latest 55m ago
150last 24h
877last 7d
146● bullish (7d)
96● bearish (7d)
214publishers
AllMacro212Earnings108M&A125Regulatory21Product21Analyst17
✕ clear all filterssentiment: bearishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Carnival hit by rising oil costs as BofA cuts price target
Proactive8h agobearish
Carnival hit by rising oil costs as BofA cuts price target

Carnival Corp (NYSE:CCL) shares have fallen 27% since August as surging oil prices raise concerns about fuel costs, prompting Bank of America to cut its price target on the cruise operator to $38 from $42 while maintaining a ‘buy’ rating. The broker said Carnival, as the only unhedged major...

Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine
Benzinga8h agobearish
Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine

Merck & Co. Inc. (NYSE:MRK) on Thursday announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema (DME). DME is a serious eye complication of diabetes where high blood sugar damages tiny retinal blood vessels, causing them to leak fluid into the macula (the central part of the retina responsible for sharp vision) and making it swell. BRUNELLO is the first of two Phase 2b/3 trials evaluating remigromig (MK-3000, formerly EYE103), an investigational

Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?
Insider Monkey9h agobearish
Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?

Inhibrx Biosciences, Inc. (NASDAQ:INBX) delivered the kind of clinical update that would normally be expected to get investors’ attention. Its experimental cancer drug INBRX-106, combined with Merck’s Keytruda, produced a confirmed response rate nearly twice that of Keytruda alone in a Phase 2 head and neck cancer study. The results were even stronger among a […]

Ford Stock Falls as Hyundai Is Set to Outsell Them for the First Time Ever
Barrons.com9h agobearish
Ford Stock Falls as Hyundai Is Set to Outsell Them for the First Time Ever

Shares of Ford Motor Company fell nearly 2% Thursday following a report from Cox Automotive forecasting that South Korea’s Hyundai will outsell the American car company in the U.S. for the first time ever in the third quarter. The automotive research firm projects that Hyundai will sell 511,421 new vehicles during the three months ending on Sept. 30, versus Ford’s 504,172. The fastest growth area for Hyundai in the U.S. has been for its hybrid vehicles, specifically its Santa Fe crossover sport-utility vehicle, Sonata sedan, and Tucson crossover SUV.

Investing.com10h agobearish
Similarweb stock falls after naming new CEO

Investing.com -- SimilarWeb Ltd (NYSE:SMWB) shares fell over 7% Thursday following the company's announcement that Michael Akkerman will become Chief Executive Officer, effective November 2, 2026.

Investing.com10h agobearish
Google to test custom AI chips in space on upcoming SpaceX mission

Investing.com -- Alphabet Inc's (NASDAQ:GOOGL) Google has officially launched Project Suncatcher, an ambitious orbital computing initiative aimed at deploying its proprietary artificial intelligence chips into space to bypass growing terrestrial energy and infrastructure constraints. The tech giant announced Thursday that it is preparing to launch a prototype satellite equipped with its Trillium Tensor Processing Units (TPUs) aboard SpaceX's (NASDAQ:SPCX) upcoming Transporter-18 rideshare missio